Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

2-Methoxyestradiol, a promising anticancer agent.

Nehal J Lakhani1, Mohamadi A Sarkar, Jurgen Venitz

  • 1Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

Pharmacotherapy
|February 18, 2003
PubMed
Summary

2-Methoxyestradiol, a metabolite of natural estrogens, shows promise in cancer treatment by inducing apoptosis and inhibiting angiogenesis. Clinical trials indicate its safety and potential efficacy in breast and prostate cancers, independent of estrogen receptors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: first clinical agent targeting APE1/Ref-1 in cancer.

The oncologist·2025
Same author

IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trial.

The oncologist·2025
Same author

Physiologically Based Pharmacokinetic Modeling to Predict Nicotine Pharmacokinetics of Nicotine Pouches Under Naturalistic Use Conditions.

Journal of clinical pharmacology·2025
Same author

A Phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/Ref-1 in Cancer.

medRxiv : the preprint server for health sciences·2025
Same author

Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study.

Haematologica·2025

Area of Science:

  • Endocrinology and Metabolism
  • Cancer Biology
  • Pharmacology

Background:

  • Estrogens are metabolized to catecholestrogens, which are further converted to 2-methoxyestradiol.
  • 2-Methoxyestradiol exhibits anti-tumorigenic properties, including potent apoptosis induction and antiangiogenic activity.
  • Its mechanism involves microtubule stabilization and is independent of estrogen receptors alpha and beta.

Purpose of the Study:

  • To investigate the anti-cancer and cardioprotective effects of 2-methoxyestradiol.
  • To evaluate the safety and efficacy of 2-methoxyestradiol in clinical trials for various cancers.
  • To explore its distinct mechanism of action independent of estrogen receptor signaling.

Main Methods:

  • Preclinical studies assessing apoptotic and antiangiogenic activities.

Related Experiment Videos

  • Phase I clinical trials evaluating safety and tolerability of 2-methoxyestradiol in breast cancer patients.
  • Phase II randomized trial assessing efficacy in hormone-refractory prostate cancer.

    • Main Results:

    • 2-Methoxyestradiol demonstrated potent apoptotic and antiangiogenic effects in preclinical models.
    • Phase I trials showed significant reduction in bone pain and analgesic intake in some breast cancer patients with no major adverse effects.
    • Phase II trials in prostate cancer patients indicated good tolerability with prostate-specific antigen stabilization and declines.

    Conclusions:

    • 2-Methoxyestradiol possesses significant antiproliferative and apoptotic activities, mediated independently of estrogen receptors.
    • Clinical trials suggest 2-methoxyestradiol is well-tolerated and shows potential therapeutic benefits in breast and prostate cancers.
    • Further clinical trials are ongoing to explore higher dosages and efficacy in various malignancies.